Hopkinson Craig C., EVP of R&D and Chief Medical Officer at Alkermes plc (ALKS), has demonstrated a clear selling bias in recent transactions, with no open-market purchases recorded in the past year. Since November 2025, Hopkinson has executed 14 sales totaling approximately $2.3 million, including multiple six-figure dispositions. Notable transactions include a $273,441 sale on November 3, 2025, followed by a $267,485 sale on March 2, 2026—the largest single transaction in the dataset. The sales appear systematic, with transactions clustered in early 2026, including four sales exceeding $100,000 between February 5 and February 23. Smaller option-related transactions (coded "M") occurred alongside many of these sales, typically valued at $96,700, except for a $72,486 transaction on December 3, 2025. The sole buy activity—a $72,486 acquisition on that same December date—appears linked to option exercises rather than discretionary purchases. This pattern suggests ongoing monetization of equity compensation, with all activity concentrated in ALKS stock. The absence of recent buys and sustained selling activity through March 2026 indicates a consistent reduction in Hopkinson's position in the biopharmaceutical company.
AI-assisted summary